Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc. > Midatech at $1.0475
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(92)
•••
Comment by prophetoffactzon Dec 31, 2022 3:10pm
59 Views
Post# 35198597

RE:RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475

RE:RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475If Biodexa and Ladenberg Thalmann did it right the Armistice Capital financing significantly undervalues Biodexa to virtually guarantee that the US$20 million gets on Biodexa's balance sheet. The last thing Biodexa needs is to be caught without cash before it hits key catalysts in this market. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities